New Jersey S2392 authorizes medical cannabis for treating sickle cell anemia.
New Jersey S2392 amends existing law to include sickle cell anemia as a qualifying medical condition for the medical use of cannabis. Sickle cell anemia is an inherited blood disorder characterized by chronic anemia and periodic episodes of pain. The bill allows patients with this condition to use cannabis to treat or alleviate symptoms. The medical use of cannabis includes the acquisition, possession, transport, or use of cannabis or paraphernalia by a registered qualifying patient. The bill takes effect immediately upon enactment.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.